热门资讯> 正文

Viridian Therapeutics推出2.5亿美元的同时债务和股权发行

2026-05-06 04:24

Viridian Therapeutics, Inc.(VRDN) 0
安进公司(AMGN) 0

Viridian Therapeutics (NASDAQ: VRDN) on Tuesday said that it has commenced concurrent public offerings of $150 million in convertible senior notes due 2032 and $100 million of common stock and convertible preferred stock.
The company said it may grant underwriters a 30-day option to purchase up to an additional 15% of securities in each offering.
Viridian plans to use the proceeds to repay outstanding debt, fund market expansion studies and research and development, and for general corporate purposes.
VRDN -5.23% after hours to $17.80.
Source: Press Release

More on Viridian Therapeutics

Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen
Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease - Slideshow
Stocks to watch on Monday after market: VRDN, BSX, MTB, AL
Viridian plunges on topline late-stage results for elegrobart for thyroid eye disease

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。